Skip to main content
logo
Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
13.92
+0.30 (2.20%)
Sep 1, 2026, 11:02 AM EDT - Market open

Summit Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
----0.711.81
Revenue
----0.711.81
Revenue Growth
-----61.03%110.35%
Gross Profit
----0.711.81
Selling, General & Admin
306.11556.7560.2129.2626.7423.61
Research & Development
568.74537.67150.7859.475285.35
Other Operating Expenses
-----14.42-20.97
Operating Expenses
874.841,094210.9988.7464.3388
Operating Income
-874.84-1,094-210.99-88.74-63.62-86.19
Interest Expense
---8.69-16.46-4.4-0.24
Interest & Investment Income
18.915.513.4710.41.51-
Currency Exchange Gain (Loss)
-0.64-0.61-0.11.03-4.11-2.14
Other Non Operating Income (Expenses)
0.5-0.05--0.250.3-0.04
EBT Excluding Unusual Items
-856.09-1,080-206.31-94.01-70.31-88.6
Asset Writedown
-----8.47-
Pretax Income
-856.09-1,080-221.32-614.93-78.78-88.6
Net Income
-856.09-1,080-221.32-614.93-78.78-88.6
Net Income to Common
-856.09-1,080-221.32-614.93-78.78-88.6
Net Income Growth
------
Shares Outstanding (Basic)
76674871962019392
Shares Outstanding (Diluted)
76674871962019392
Shares Change
4.03%4.06%15.96%220.50%109.60%32.67%
EPS (Basic)
-1.12-1.44-0.31-0.99-0.41-0.96
EPS (Diluted)
-1.12-1.44-0.31-0.99-0.41-0.96
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-459.82-323.59-142.25-76.89-42.21-72.89
Free Cash Flow Per Share
-0.60-0.43-0.20-0.12-0.22-0.79
Gross Margin
----100.00%100.00%
Operating Margin
-----9024.25%-4764.29%
Profit Margin
-----11174.75%-4897.84%
Free Cash Flow Margin
-----5986.67%-4029.46%
EBITDA
-874.67-1,094-210.9-88.54-62.36-84.84
D&A For EBITDA
0.170.150.090.21.261.35
EBIT
-874.84-1,094-210.99-88.74-63.62-86.19
SEC Filings: 10-K · 10-Q